Atlas Venture Life Science Advisors, LLC 13F Holdings · Q2 2026
Atlas Venture Life Science Advisors, LLC reported 7 securities worth $881.29M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: KYMR (37.05%), DYN (17.14%), SION (14.95%). Among its top 25 positions this quarter: 1 new, 1 added, 3 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | $326.5M | 37.05% | 2.8M | Trimmed |
| 2 | DYN | Dyne Therapeutics, Inc. | $151.0M | 17.14% | 6.8M | Trimmed |
| 3 | SION | Sionna Therapeutics, Inc. | $131.8M | 14.95% | 3.0M | Hold |
| 4 | KLRA | Kailera Therapeutics, Inc. | $113.9M | 12.93% | 5.2M | New |
| 5 | IRON | Disc Medicine, Inc. | $110.7M | 12.56% | 1.5M | Hold |
| 6 | QTTB | Q32 Bio, Inc. | $34.6M | 3.93% | 2.7M | Added |
| 7 | KRRO | Korro Bio, Inc. | $12.7M | 1.44% | 962,884 | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR